Concerns rise among Korean drug makers

The domestic pharmaceutical sector is expected to face an inevitable blow following the Korean government's plan to deny a local pharmaceutical company the license to sell generic drugs for at least 12 months, if the U.S. company that produced the original drug file a lawsuit over patent infringement.

During the next National Assembly session, the Ministry of Health and Welfare plans to prop...